CB2 Insights (CSE:CBII) (OTCQB:CBIIF), a medical cannabis analytics company, is adding new talent to its board of directors in the form of retired Johnson & Johnson (NYSE:JNJ) executive Peter Cummins.
Cummins worked for more than two decades at Johnson & Johnson in a variety of executive roles, overseeing research and development, external innovation, regulatory affairs and other areas over the course of his career.
Before that he worked in regulatory and scientific affairs at The Procter & Gamble Company (NYSE:PG) and served the director of pharmacy at Cambridge Memorial Hospital.
READ: CB2 Insights expands data analytics platform to the UK through new medical cannabis pilot program
“Peter has extensive experience in traditional pharmaceutical research and development,” said CB2 chairman David Danziger.
“He brings a crucial understanding and network to CB2 Insights that will undoubtedly help to unlock the value of the Company’s data assets moving forward.”
The appointment brings the size of CB2’s board up to seven members, the majority of whom serve as independent directors.
The Toronto-based company gathers point-of-care data in the medical cannabis space with the goal of making treatment more mainstream.
CB2 shares were 2.6% higher on Wednesday lunchtime at $0.195.
-- Updates share price --
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel